Skip to content
Awesome – Lifestyle
Author:
Synklino
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
May 28, 2026
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
March 4, 2026